title: Optimal therapy sequencing in metastatic castration-resistant prostate cancer.
abstract: Prostate cancer is the most common cancer in men worldwide, accounting for approximately 242,000 new cases and 28,000 deaths annually in the USA. Although localized disease is often curable, advanced disease is generally not, especially when the cancer becomes castration-resistant and metastasizes to bone. Fortunately, advances in research have led to the recent approval of several novel therapies for the treatment of metastatic disease, and many other promising agents are in development. With this success arises the distinct challenge of optimizing both sequencing and the design of rational combinations with these agents. This review focuses on practical and experimental approaches to this challenge.
authors.affiliation: Department of Genitourinary Medical Oncology, Unit 1374, MD Anderson Cancer Center, 1155 Pressler St., Houston, TX, 77030, USA.
authors.forename: Sausan
authors.initials: S
authors.lastname: Abouharb
authors.forename: Paul G
authors.initials: PG
authors.lastname: Corn
mesh_terms: D059002:Androgen Receptor Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D002369:Castration / Q000379:methods*; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D059002:Androgen Receptor Antagonists; D018931:Antineoplastic Agents, Hormonal